This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 11, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of
Thomas C. Reynolds, M.D., Ph.D., to its Board of Directors. A biotechnology industry veteran, Dr. Reynolds joins the Board with more than 20 years of oncology drug development experience, including direct oversight in the development and approval of the hematologic cancer drug ADCETRIS
"Dr. Reynolds' proven drug development expertise and valuable industry perspective make him a welcome addition to our Board," said
Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "His appointment is particularly timely as we prepare for the expansion of our clinical development program for Pracinostat in the months ahead."
Dr. Reynolds served as Chief Medical Officer of Seattle Genetics from
March 2007 until his retirement in
February 2013. While at Seattle Genetics, he was responsible for building and leading an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of ADCETRIS
®, an antibody-drug conjugate approved to treat anaplastic large cell lymphoma and Hodgkin's lymphoma.
Previously, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM
®. Prior to joining ZymoGenetics, he was Vice President, Clinical Affairs at Targeted Genetics. Dr. Reynolds received his M.D. and Ph.D. in Biophysics from
Stanford University and a B.A. in Chemistry from
"I am delighted to join the Board of MEI Pharma at such an exciting time for the company," said Dr. Reynolds. "I believe that MEI Pharma is poised to make an immediate impact in the oncology arena with its lead drug candidate, Pracinostat. I look forward to working closely with the rest of the Board and management team to execute the optimal clinical development and marketing approval strategy for Pracinostat and ultimately realize its significant potential."